A methodology study in healthy subjects to evaluate the effect of AZD8309 after nasal administration of Lipopolysaccharide (LPS)

Study identifier:D1511M00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, double-blind, placebo-controlled, two-way crossover, single-centre methodologhy study in healthy subjects to evaluate the effect of oral dosing with AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS).

Medical condition

Healthy

Phase

N/A

Healthy volunteers

Yes

Study drug

AZD8309

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Mar 2009

Primary Completion Date: -

Study Completion Date: 01 Oct 2009

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Oct 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 AZD8309	Drug: AZD8309 oral solution 30 mg/g, dose: 300mg bid for 3 days
Placebo Comparator: 2 Placebo	Drug: AZD8309 oral solution 30 mg/g, dose: 300mg bid for 3 days

Documents available

Trial Results Summaries
Available here

Contacts

Contact

Malin Fageras

46 46 336000

[email protected]

Investigators

Principal Investigator

Lars Olaf Cardell

Department of Otorhinolaryngology, Malmö University Hospital, Sweden